核心概念
Patients with large ischemic strokes and significant brain tissue damage may benefit from thrombectomy, despite not meeting the primary endpoint in recent trials.
要約
The content discusses the TESLA trial and a meta-analysis (MAGNA) focusing on thrombectomy benefits in patients with large core infarcts. Key highlights include:
- TESLA trial showed trends towards thrombectomy benefits for 90-day outcomes.
- Previous trials demonstrated benefits of endovascular therapy in large core infarcts.
- TESLA study used non-contrast CT scans for patient selection, showing smaller treatment effects.
- MAGNA meta-analysis confirmed thrombectomy efficacy in large core ischemic strokes.
- Results from TESLA align with previous trials, emphasizing thrombectomy's efficacy and safety.
- Further trials like TENSION and LASTE are expected to provide more insights.
統計
The 90-day uw-MRS scores were 2.93 in the thrombectomy group vs 2.27 in the control group.
Major neurological improvement occurred in 26% of thrombectomy patients vs 13% of controls.
Symptomatic ICH occurred in 3.97% of thrombectomy vs 1.34% of control patients.
引用
"They also showed better neurological improvement and a higher chance of achieving a good outcome." - Osama Zaidat
"The benefit persists across the spectrum of age, clinical severity, and time, with clear benefit up to an estimated ischemic core volume of 150 mL." - Amrou Sarraj